How many drugs treat Meningococcal meningitis?

Drug Landscape tracks 10 marketed treatments for Meningococcal meningitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/meningococcal-meningitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Meningococcal meningitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Meningococcal meningitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Meningococcal meningitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Azo Gantrisin	sulfafurazole	Alra	Sulfonamide Antimicrobial	Endothelin-1 receptor	1971-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Chlorocidin	CHLORAMPHENICOL	Parkedale	Amphenicol-class Antibacterial	Cytochrome P450 3A4	1950-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
penicillin	penicillin	Karlstad University		Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pai Holdings Pharm · 2 drugs in Meningococcal meningitis
Bristol-Myers Squibb · 1 drug in Meningococcal meningitis
Centre Hospitalier Universitaire Vaudois · 1 drug in Meningococcal meningitis
Generic (originally Roche) · 1 drug in Meningococcal meningitis
Karlstad University · 1 drug in Meningococcal meningitis
Parkedale · 1 drug in Meningococcal meningitis
Pfizer · 1 drug in Meningococcal meningitis
Sterimax · 1 drug in Meningococcal meningitis
Alra · 1 drug in Meningococcal meningitis
Tel-Aviv Sourasky Medical Center · 1 drug in Meningococcal meningitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Meningococcal meningitis:

Cite this brief

Drug Landscape (2026). Meningococcal meningitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/meningococcal-meningitis. Accessed 2026-06-10.

Meningococcal meningitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing